Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 373

1.

Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ.

PLoS One. 2012;7(10):e44372. doi: 10.1371/journal.pone.0044372. Epub 2012 Oct 2.

PMID:
23056179
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT.

Invest New Drugs. 2011 Dec;29(6):1123-31. doi: 10.1007/s10637-010-9451-1. Epub 2010 May 15.

PMID:
20467883
[PubMed - indexed for MEDLINE]
3.

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B.

Neuro Oncol. 2010 Aug;12(8):822-33. doi: 10.1093/neuonc/noq017. Epub 2010 Feb 23.

PMID:
20179017
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG.

Neoplasia. 2009 May;11(5):448-58, 2 p following 458.

PMID:
19412429
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.

Pozo N, Zahonero C, Fernández P, Liñares JM, Ayuso A, Hagiwara M, Pérez A, Ricoy JR, Hernández-Laín A, Sepúlveda JM, Sánchez-Gómez P.

J Clin Invest. 2013 Jun 3;123(6):2475-87. doi: 10.1172/JCI63623. Epub 2013 May 1.

PMID:
23635774
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.

de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS.

Neuro Oncol. 2007 Oct;9(4):412-23. Epub 2007 Jul 10.

PMID:
17622648
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.

Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S.

J Transl Med. 2014 Jan 17;12:13. doi: 10.1186/1479-5876-12-13. Erratum in: J Transl Med. 2014;12:126. Mukthavavam, Rajesh [corrected to Mukthavaram, Rajesh].

PMID:
24433351
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.

Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA.

Science. 2007 Oct 12;318(5848):287-90. Epub 2007 Sep 13.

PMID:
17872411
[PubMed - indexed for MEDLINE]
Free Article
9.

The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.

D'Amico R, Lei L, Kennedy BC, Sisti J, Ebiana V, Crisman C, Christensen JG, Gil O, Rosenfeld SS, Canoll P, Bruce JN.

Neurol Res. 2012 Apr;34(3):252-61. doi: 10.1179/1743132812Y.0000000005. Epub 2012 Mar 5.

PMID:
22449730
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M, Woolfenden S, Boskovitz A, Raval A, Bronson RT, Pfannl R, Whittaker CA, Housman DE, Charest A.

Cancer Res. 2011 Dec 1;71(23):7198-206. doi: 10.1158/0008-5472.CAN-11-1514. Epub 2011 Oct 10.

PMID:
21987724
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.

PMID:
19584231
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

PMID:
15289342
[PubMed - indexed for MEDLINE]
Free Article
13.

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9. doi: 10.1073/pnas.1211962109. Epub 2012 Aug 13.

PMID:
22891331
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

PMID:
15475436
[PubMed - indexed for MEDLINE]
Free Article
15.

Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.

Nam HJ, Ching KA, Kan J, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ.

Mol Cancer Ther. 2012 Feb;11(2):439-51. doi: 10.1158/1535-7163.MCT-11-0494. Epub 2011 Dec 1.

PMID:
22135232
[PubMed - indexed for MEDLINE]
Free Article
16.

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.

PMID:
21858220
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Raizer JJ.

J Neurooncol. 2005 Aug;74(1):77-86. Review.

PMID:
16078112
[PubMed - indexed for MEDLINE]
18.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

PMID:
19417025
[PubMed - indexed for MEDLINE]
Free Article
19.

Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.

Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15984-9. doi: 10.1073/pnas.1113416108. Epub 2011 Sep 6.

PMID:
21896743
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.

Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP.

Int J Cancer. 2012 Jun 1;130(11):2693-702. doi: 10.1002/ijc.26303. Epub 2011 Sep 14.

PMID:
21792888
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk